share_log

10-K: FY2024 Annual Report

10-K: FY2024 Annual Report

10-K：2024财年年报
美股SEC公告 ·  2024/07/30 04:05

Moomoo AI 已提取核心信息

Heart Test Laboratories reported FY2024 financial results with revenue increasing to $19,000 from $5,000 in FY2023. The company recorded a net loss of $6.6 million compared to $6.4 million in the previous year. Research and development expenses rose 17% to $2.9 million, primarily due to cloud platform development and FDA submission preparation costs.The company made significant strategic progress, entering into multiple license agreements with Mount Sinai in September 2023 to commercialize AI-ECG algorithms. HeartSciences is preparing for FDA 510(k) submission of its MyoVista wavECG device in Q1 2025, following FDA confirmation of the submission pathway in December 2023. The company also launched its MyoVista Insights Cloud Platform development for hosting AI-ECG algorithms.As of April 30, 2024, HeartSciences had $5.8 million in cash, up from $1.7 million the previous year, strengthened by successful capital raises through ATM facilities and equity lines. The company secured key patents in Europe, Canada and India for its ECG technology, while implementing a 1-for-100 reverse stock split in May 2024 to maintain Nasdaq listing compliance.
Heart Test Laboratories reported FY2024 financial results with revenue increasing to $19,000 from $5,000 in FY2023. The company recorded a net loss of $6.6 million compared to $6.4 million in the previous year. Research and development expenses rose 17% to $2.9 million, primarily due to cloud platform development and FDA submission preparation costs.The company made significant strategic progress, entering into multiple license agreements with Mount Sinai in September 2023 to commercialize AI-ECG algorithms. HeartSciences is preparing for FDA 510(k) submission of its MyoVista wavECG device in Q1 2025, following FDA confirmation of the submission pathway in December 2023. The company also launched its MyoVista Insights Cloud Platform development for hosting AI-ECG algorithms.As of April 30, 2024, HeartSciences had $5.8 million in cash, up from $1.7 million the previous year, strengthened by successful capital raises through ATM facilities and equity lines. The company secured key patents in Europe, Canada and India for its ECG technology, while implementing a 1-for-100 reverse stock split in May 2024 to maintain Nasdaq listing compliance.
心脏测试实验室公布了2024财年的财务结果，营业收入从2023财年的5000美元增加至19000美元。公司记录了660万美元的净亏损，相比之下，去年为640万美元。研发费用增长了17%，达到290万美元，主要是由于云平台开发和FDA提交准备成本。公司在战略上取得了显著进展，在2023年9月与西奈山医院签订了多项许可协议，以商业化人工智能心电图算法。HeartSciences正在为其MyoVista wavECG设备的FDA 510(k)提交做准备，预计在2025年第一季度进行，FDA在2023年12月确认了提交途径。公司还启动了MyoVista Insights云平台的开发，以托管人工智能心电...展开全部
心脏测试实验室公布了2024财年的财务结果，营业收入从2023财年的5000美元增加至19000美元。公司记录了660万美元的净亏损，相比之下，去年为640万美元。研发费用增长了17%，达到290万美元，主要是由于云平台开发和FDA提交准备成本。公司在战略上取得了显著进展，在2023年9月与西奈山医院签订了多项许可协议，以商业化人工智能心电图算法。HeartSciences正在为其MyoVista wavECG设备的FDA 510(k)提交做准备，预计在2025年第一季度进行，FDA在2023年12月确认了提交途径。公司还启动了MyoVista Insights云平台的开发，以托管人工智能心电图算法。截至2024年4月30日，HeartSciences的现金余额为580万美元，较去年170万美元有所增长，这得益于通过ATM设施和股权渠道成功融资。公司在欧洲、加拿大和印度为其心电图科技获得了关键专利，同时在2024年5月实施了一次性100股换1股的反向股票拆分，以维持纳斯达克上市合规性。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    NanoVibronix
    NAOV
    -- 4.4500
    Outset Medical
    OM
    -- 11.280
    Autonomix Medical
    AMIX
    -- 2.190
    Modular Medical
    MODD
    -- 1.050
    ReShape Lifesciences
    RSLS
    -- 0.6960
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日